MetaVia (MTVA) Operating Expenses (2015 - 2026)
MetaVia's (MTVA) quarterly Operating Expenses came in at $2.0 million in Q4 2025, down 63.37% YoY from $5.6 million in Q4 2024, and down 41.12% on a QoQ basis from $3.5 million in Q3 2025.
MetaVia (MTVA) Operating Expenses (2015 - 2026) Analysis & Trends
MetaVia (MTVA) has 9 years of Operating Expenses data on file, last reported at $2.0 million in Q4 2025.
- Quarterly Operating Expenses fell 63.37% year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.7 million (down 52.42% YoY) and the FY2025 annual result came in at $13.7 million, down 52.42% from the prior year.
- Operating Expenses declined to $2.0 million in Q4 2025, from $3.5 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $10.4 million in Q4 2022 to a low of $2.0 million in Q4 2025.
- A 4-year average of $5.1 million and a median of $4.1 million in 2025 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2024 — Operating Expenses soared 173.06% — and 2025, when it plunged 63.37%.
- Tracing MTVA's Operating Expenses over 4 years: stood at $10.4 million in 2022, then slumped by 75.84% to $2.5 million in 2023, then soared by 121.63% to $5.6 million in 2024, then sank by 63.37% to $2.0 million in 2025.
- The last three Operating Expenses figures came in at $2.0 million (Q4 2025), $3.5 million (Q3 2025), and $4.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - | 5.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.39 Mn |
| Dec 31, 2025 | 2.05 Mn |
| Sep 30, 2025 | 3.48 Mn |
| Jun 30, 2025 | 4.30 Mn |
| Mar 31, 2025 | 3.89 Mn |
| Dec 31, 2024 | 5.59 Mn |
| Sep 30, 2024 | 6.26 Mn |
| Jun 30, 2024 | 10.08 Mn |
| Mar 31, 2024 | 6.88 Mn |
| Mar 31, 2023 | 2.52 Mn |
| Dec 31, 2022 | 10.43 Mn |
| Sep 30, 2022 | 3.10 Mn |
| Jun 30, 2022 | 3.22 Mn |
| Sep 30, 2019 | 2.32 Mn |
| Jun 30, 2019 | 2.35 Mn |
| Mar 31, 2019 | 2.80 Mn |
| Dec 31, 2018 | 3.30 Mn |
| Sep 30, 2018 | 5.91 Mn |
| Jun 30, 2018 | 6.53 Mn |
| Mar 31, 2018 | 7.06 Mn |